Recce Pharmaceuticals Ltd. (AU:RCE)
ASX:RCE
Want to see AU:RCE full AI Analyst Report?
RCE Stock Chart & Stats
AU$0.41
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.41
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.29 - AU$0.73
Previous CloseN/A
Volume21.12K
Average Volume (3M)154.69K
Market Cap
AU$161.94M
Enterprise ValueAU$169.95M
Total Cash (Recent Filing)AU$602.99K
Total Debt (Recent Filing)AU$11.26M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding289,183,400
10 Day Avg. Volume112,630
30 Day Avg. Volume154,688
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)-22.52
Price to Sales (P/S)9.15
P/FCF Ratio-3.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)AU$4.25M
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GrowthSustained free cash flow growth (+51.97%) indicates the company can increasingly convert resources into discretionary cash. Over 2–6 months this can extend clinical runway, reduce near-term dilution needs, and provide optionality to fund trials or partnerships even if operating cash remains weak.
Return On EquityA positive ROE (7.02%) signals some efficiency in using shareholder capital to generate returns. For a clinical-stage biotech this suggests the business can produce value from invested equity as programs progress, which supports potential value creation when clinical milestones are achieved.
Focused Anti-infective PipelineA diversified pipeline of synthetic broad-spectrum anti-infectives across IV, oral and topical routes targets persistent structural demand from antibiotic resistance. This product breadth improves commercial pathways and long-term relevance if clinical development translates into approvals or partner deals.
Bears Say
Revenue DeclineA 21.73% drop in revenue reflects weakening top-line momentum that undermines internal funding capacity. Over the medium term this elevates reliance on external financing for R&D, increases dilution risk, and constrains the company’s ability to scale development or commercial activities.
Deep Negative MarginsExtremely negative margins (net -285%, EBIT -271%) indicate the company is burning far more than it earns, signaling structural unprofitability while in clinical development. Such high burn rates shorten runway, force frequent financing, and raise execution risk absent major operational change.
Negative Equity And LeverageNegative equity and a debt-to-equity of -3.53 point to a stressed balance sheet and limited financing flexibility. This structural weakness increases refinancing and covenant risks, complicates partnership negotiations, and heightens insolvency concerns if cash generation or funding access deteriorates.
Recce Pharmaceuticals Ltd. News
RCE FAQ
What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?
Recce Pharmaceuticals Ltd. lowest share price was AU$0.28 and its highest was AU$0.73 in the past 12 months.
What is Recce Pharmaceuticals Ltd.’s market cap?
Recce Pharmaceuticals Ltd.’s market cap is AU$161.94M.
When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?
Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 89 days.
How were Recce Pharmaceuticals Ltd.’s earnings last quarter?
Recce Pharmaceuticals Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.057 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.057.
Is Recce Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Recce Pharmaceuticals Ltd. pay dividends?
Recce Pharmaceuticals Ltd. does not currently pay dividends.
What is Recce Pharmaceuticals Ltd.’s EPS estimate?
Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recce Pharmaceuticals Ltd. have?
Recce Pharmaceuticals Ltd. has 289,183,400 shares outstanding.
What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?
Recce Pharmaceuticals Ltd. reported an EPS of -AU$0.057 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.917%.
Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:RCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recce Pharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RCE Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.63%
12-Months-Change
Fundamentals
Return on Equity
279.21%
Trailing 12-Months
Asset Growth
-51.48%
Trailing 12-Months
Company Description
Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
Technical Analysis
Amplia Therapeutics
―
Imugene
―
Alterity Therapeutics
―
Prescient Therapeutics Limited
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---